PATENT CLAIM ANALYSIS

Application Number: 16204471
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-06
Patent Classification: ["514", "342000"]

Abstract:
The present invention relates to a pharmaceutical combination comprising LSZ102 and alpelisib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with PI3K inhibition is beneficial in, for example, the treatment of cancers.

Claim (Index 14):
The method of  claim 13  wherein the mutations are selected from the group consisting of D538G, E380Q, Y537S, Y537N and Y537C.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 98.0
- Lexical Diversity: 1.36585
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14645578', '15939218', '15167373', '16475980', '15075373']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7652199400986076
- 35 USC 102 Novelty (BERT): 0.5398640277510203
- Combined Prediction Score: 0.7426843488638489
- Mean Citation Score: 311.492662
- Max Citation Score: 367.01968
- Similarity Product: 226.65674986355785

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test